Chemotherapeutic agents have shown augment mutational load and neoantigen presentation, suppress the immune-suppressive cells, sensitize tumor cells to effector cytokines produced by T cells, induce the expression of major histocompatibility complex class I (MHC-I) and PD-L1 on tumor cells (65–73). Here, CD274 is linked to neoplasm.